The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin

Clinical Pharmacology and Therapeutics

Volumn 60, Issue 5, 1996, Pages 512-521

  Hamelin, Bettina A ^a,b   Turgeon, Jacques ^a,b   Vallée, François ^a,b   Bélanger, Pierre Maxime ^a,b   Paquet, François ^a,b   LeBel, Marc ^a,b,c  

^a Quebec Heart Institute ^*

^b LAVAL UNIVERSITY   (Canada)

^c UNIVERSITÉ LAVAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; DEBRISOQUINE; DRUG METABOLITE; FLUOXETINE; NORFLUOXETINE; NORSERTRALINE; SERTRALINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; DEMETHYLATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG METABOLISM; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0029827303     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(96)90147-2     Document Type: Article

References (44)

1. Lemberger L, Bergstrom RF, Wolen RL, Farid NA, Enas GG, Aronoff GR. Fluoxetine: clinical pharmacology and physiologic disposition. J Clin Psychiatry 1985;46:14-9.
2. Warrington SJ. Clinical implications of the pharmacology of sertraline. Int Clin Psychopharmacol 1991; 6:11-21.
3. Altamura AC, Moro AR, Percudani M. Clinical pharmacokinetics of fluoxetine. Clin Pharmacokinet 1994; 26:201-14.
4. Heym J, Koe BK. Pharmacology of sertraline: a review. J Clin Psychiatry 1988;49:40-5.
5. Goodnick PJ. Pharmacokinetics of second generation antidepressants: fluoxetine. Psychopharm Bull 1991; 27:503-12.
6. Koe BK, Weissman A, Welch WM, Browne RG. Sertraline, 1S,4S-N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthylamine, a new uptake inhibitor with selectivity for serotonin. J Pharmacol Exp Ther 1983;226:686-700.
7. Tremaine LM, Welch WM, Ronfeld RA. Metabolism and disposition of the 5-hydroxytryptamine uptake blocker sertraline in the rat and dog. Drug Metab Dispos 1989;17:542-50.
8. Brøsen K, Gram LF. Clinical significance of the sparteine/debrisoquine oxidation polymorphism. Eur J Clin Invest 1989;36:537-47.
9. Spina E, Martines C, Caputi AP, Cobelada J, Pinas B, Carrillo JA, et al. Debrisoquine oxidation phenotype during neuroleptic monotherapy. Eur J Clin Invest 1991;41:467-70.
10. Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE. The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol 1992;34:262-5.
11. Stevens JC, Wrighton SA. Interaction of the enantiomers of fluoxetine and norfluoxetine with human liver cytochromes P450. J Pharmacol Exp Ther 1993; 266:964-71.
12. Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE. The effect of paroxetine and other specific 5-HT re-uptake inhibitors on cytochrome P450IID6 activity in human liver microsomes. Br J Clin Pharmacol 1991;32:658P-9P.
13. Bergstrom RF, Peyton AL, Lemberger L. Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction. Clin Pharmacol Ther 1992;51:239-48.
14. Messiha FS. Fluoxetine: adverse effects and drug-drug interactions. Clin Toxicol 1993;31:603-30.
15. Gram LF. Fluoxetine. N Engl J Med 1994;331:1354-61.
16. Wong DT, Bymaster FP, Engleman EA. Prozac (fluoxetine, Lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: twenty years since its first publication. Life Sci 1995;57:411-41.
17. Cohn CK, Shrivastava R, Mendels J, Cohn JB, Fabre LF, Claghorn JL, et al. Double-blind, multicenter comparison of sertraline and amitriptyline in elderly depressed patients. J Clin Psychiatry 1990; 51:28-33.
18. Apseloff G, Wilner KD, von Deutsch DA, Henry EB, Tremaine LM, Gerber N, et al. Sertraline does not alter steady-state concentrations or renal clearance of lithium in healthy volunteers. J Clin Pharmacol 1992; 32:643-6.
19. Preskorn SH, Magnus RD. Inhibition of hepatic P-450 isoenzymes by serotonin selective reuptake inhibitors: in vitro and in vivo findings and their implications for patient care. Psychopharm Bull 1994;30:251-9.
20. Bergstrom RF, Lemberger L, Farid NA, Wolen RL. Clinical pharmacology and pharmacokinetics of fluoxetine: a review. Br J Psychiatry 1988;153(suppl 3):47-50.
21. Benfield P, Heel RC, Lewis SP. Fluoxetine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs 1986;32:481-508.
22. Van Harten J. Clinical pharmacokinetics of selective serotonin reuptake inhibitors. Clin Pharmacokinet 1993;24:203-20.
23. Mahgoub A, Idle JR, Dring LG, Lancaster R, Smith RL. Polymorphic hydroxylation of debrisoquine in man. Lancet 1977;2:584-6.
24. 14C]-debrisoquine in man. Br J Clin Pharmacol 1979;7:257-66.
25. Tremaine LM, Joerg EA. Automated gas chromatographic electron capture assay for the selective serotonin uptake blocker sertraline. J Chromatogr 1989; 494:423-9.
26. Thomare P, Wang K, Van der Meersch-Mougeot V, Diquet B. Sensitive micromethod for column liquid chromatographic determination of fluoxetine and norfluoxetine in human plasma. J Chromatogr 1992; 583:217-21.
27. Chiou WL. Critical evaluation of the potential error in pharmacokinetic studies of using the linear trapezoidal rule method for the calculation of the area under the plasma levels-time curve. J Pharmacokinet Biopharm 1978;6:539-46.
28. Bergstrom RF, Lemberger L, Peyton AL. Drug interaction between fluoxetine and the tricyclic antidepressants imipramine and desipramine [abstract]. Pharm Res 1990;7:S254.
29. Vaughan DA. Interaction of fluoxetine with tricyclic antidepressants [abstract]. Am J Psychiatry 1988;145: 1478.
30. Rudorfer MV, Potter WZ. Combined fluoxetine and tricyclic antidepressants. Am J Psychiatry 1989;146: 562-3.
31. Achamallah NS. Visual hallucinations after combining fluoxetine and dextromethorphan [abstract]. Am J Psychiatry 1992;149:1406.
32. Stein MH. Tardive dyskinesia in a patient taking haloperidol and fluoxetine [abstract]. Am J Psychiatry 1991; 148:683.
33. Tate JL. Extrapyramidal symptoms in a patient taking haloperidol and fluoxetine. Am J Psychiatry 1989;146: 399-400.
34. Preskorn S. Targeted pharmacotherapy in depression management: comparative pharmacokinetics of fluoxetine, paroxetine and sertraline. Int Clin Psychopharmacol 1994;9(suppl 3):13-9.
35. Swims MP. Potential terfenadine-fluoxetine interaction. Ann Pharmacother 1993;27:1404-5.
36. Jalil P. Toxic reaction following the combined administration of fluoxetine and phenytoin: two case reports. J Neurol Neurosurg Psychiatry 1992;412-3.
37. Koymans L, Vermeulen NPE, van Acker SABE, te Koppele JM, Heykants JJP, Lavrijsen K, et al. A predictive model for substrates of cytochrome P450-debrisoquine (2D6). Chem Res Toxicol 1992;5:211-9.
38. Smith DA, Jones BC. Speculations on the substrate structure-activity relationship (SSAR) of cytochrome P450 enzymes. Biochem Pharmacol 1992; 44:2089-98.
39. Coutts RT, Su P, Baker GB. Involvement of CYP2D6, CYP3A4, and other cytochrome P-450 isozymes in N-dealkylation reactions. J Pharmacol Toxicol Methods 1994;31:177-86.
40. DeVane CL. Pharmacokinetics of the selective serotonin reuptake inhibitors. J Clin Psychiatry 1992;53: 13-20.
41. Brøsen K, Davidsen F, Gram LF. Quinidine kinetics after a single oral dose in relation to the sparteine oxidation polymorphism in man. Br J Clin Pharmacol 1990;29:248-53.
42. Guengerich FP, Muller-Enoch D, Blair IA. Oxidation of quinidine by human liver cytochrome P-450. Mol Pharmacol 1986;30:287-95.
43. Otton SV, Crewe HK, Lennard MS, Tucker GT, Woods HF. Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes. J Pharmacol Exp Ther 1988;247:242-7.
44. Schellens JHM, Ghabrial H, van der Wart HHF, Bakker EN, Wilkinson GR, Breimer DD. Differential effects of quinidine on the disposition of nifedipine, sparteine, and mephenytoin in humans. Clin Pharmacol Ther 1991;50:520-8.